Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis

Calès, Paul, Masliah, Claude, Bernard, Brigitte, Garnier, Pierre-Philippe, Silvain, Christine, Szostak-Talbodec, Nathalie, Bronowicki, Jean-Pierre, Ribard, Didier, Botta-Fridlund, Danièle, Hillon, Patrick, Besseghir, Kamel, Lebrec, Didier, Poynard, Thierry, Verger, Pierre, Paris, Jean-Claude, Durand, Francois, Valla, Dominique-Charles, Lemaire, Alex, Rouch, Michel, Blanchi, Alain, Ink, Olivier, Saliba, Faouzi, Galula, Gilles, Pillegand, Bernard, Davion, Thierry, Dao, Thong, Bonny, Corinne, Zarski, Jean-Pierre, Mion, Francois · 2001 · New England Journal of Medicine

Abstract

BACKGROUND: In patients with cirrhosis, pharmacologic or endoscopic treatment may control variceal bleeding. However, the effects of early administration of a somatostatin analogue followed by endoscopic treatment are unknown. METHODS: We studied the effects of treatment with vapreotide, a somatostatin analogue, begun before endoscopic treatment in 227 patients with cirrhosis who were hospitalized for acute upper gastrointestinal bleeding. The patients were randomly assigned to receive vapreotide (a 50-microg intravenous bolus followed by an infusion at a rate of 50 microg per hour for five days) or placebo within a mean (+/-SD) of 2.3+/-1.5 hours after admission. All the patients received endoscopic treatment a mean of 2.6+/-3.3 hours after the infusion was begun. After the exclusion of 31 patients whose bleeding was not caused by portal hypertension, there were 98 patients in each group. RESULTS: At the time of endoscopy, active bleeding was evident in 28 of 91 patients in the vapreotide group (31 percent), as compared with 43 of 93 patients in the placebo group (46 percent) (P=0.03). During the five-day infusion, the primary objective--survival and control of bleeding--was achieved in 65 of 98 patients in the vapreotide group (66 percent) as compared with 49 of 98 patients in the placebo group (50 percent) (P=0.02). The patients in the vapreotide group received significantly fewer blood transfusions (2.0+/-2.2 vs. 2.8+/-2.8 units, P=0.04). Overall mortality rates at 42 days were not significantly different in the two groups. CONCLUSIONS: In patients with cirrhosis and variceal bleeding, the combination of vapreotide and endoscopic treatment is more effective than endoscopic treatment alone as a method of controlling acute bleeding. However, the use of combination therapy does not affect mortality rates at 42 days.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm200101043440104

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 240

Metadata

Authors
Calès, P., Masliah, C., Bernard, B., Garnier, P.-P., Silvain, C., Szostak-Talbodec, N., Bronowicki, J.-P., Ribard, D., Botta-Fridlund, D., Hillon, P., Besseghir, K., Lebrec, D., Poynard, T., Verger, P., Paris, J.-C., Durand, F., Valla, D.-C., Lemaire, A., Rouch, M., Blanchi, A., Ink, O., Saliba, F., Galula, G., Pillegand, B., Davion, T., Dao, T., Bonny, C., Zarski, J.-P., & Mion, F.
Venue
New England Journal of Medicine
Published
2001-01-04
Volume
344
Issue
1
Pages
23-28
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2338610360
Cited by
240
References
1
FWCI
12.34
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis. https://app.cochat.ai/papers/10.1056/nejm200101043440104
The paper
Calès, P., Masliah, C., Bernard, B., Garnier, P.-P., Silvain, C., Szostak-Talbodec, N., Bronowicki, J.-P., Ribard, D., Botta-Fridlund, D., Hillon, P., Besseghir, K., Lebrec, D., Poynard, T., Verger, P., Paris, J.-C., Durand, F., Valla, D.-C., Lemaire, A., Rouch, M., . . . Mion, F. (2001). Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis. New England Journal of Medicine. https://doi.org/10.1056/nejm200101043440104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.